Gilead Sciences, Inc. (NASDAQ:GILD) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Saturday.

Several other research analysts have also commented on GILD. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 price objective (up from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Leerink Swann reaffirmed a “hold” rating and set a $74.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 25th. Cowen and Company reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Gilead Sciences in a research note on Thursday, July 27th. Jefferies Group LLC reaffirmed a “hold” rating and set a $83.00 price objective on shares of Gilead Sciences in a research note on Thursday, July 27th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a research note on Thursday, July 13th. Eleven research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and a consensus target price of $80.31.

Gilead Sciences (NASDAQ GILD) traded down 0.32% during midday trading on Friday, reaching $72.11. 6,052,601 shares of the company were exchanged. The company has a 50-day moving average of $72.61 and a 200 day moving average of $68.83. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $82.10. The firm has a market capitalization of $94.17 billion, a PE ratio of 7.83 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.08 earnings per share. Equities analysts predict that Gilead Sciences will post $8.75 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/19/gilead-sciences-inc-gild-upgraded-to-buy-by-bidaskclub.html.

In related news, EVP Gregg H. Alton sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares in the company, valued at $7,318,327.28. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders have sold 206,666 shares of company stock worth $15,223,184 in the last 90 days. Insiders own 1.30% of the company’s stock.

A number of large investors have recently modified their holdings of GILD. Private Asset Management Inc. raised its stake in shares of Gilead Sciences by 4.1% in the first quarter. Private Asset Management Inc. now owns 115,410 shares of the biopharmaceutical company’s stock worth $7,839,000 after buying an additional 4,582 shares in the last quarter. Triangle Securities Wealth Management raised its stake in shares of Gilead Sciences by 30.5% in the first quarter. Triangle Securities Wealth Management now owns 3,832 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 895 shares in the last quarter. F&V Capital Management LLC raised its stake in shares of Gilead Sciences by 3.1% in the first quarter. F&V Capital Management LLC now owns 79,450 shares of the biopharmaceutical company’s stock worth $5,396,000 after buying an additional 2,425 shares in the last quarter. Bridges Investment Management Inc. raised its stake in shares of Gilead Sciences by 65.6% in the first quarter. Bridges Investment Management Inc. now owns 59,150 shares of the biopharmaceutical company’s stock worth $4,018,000 after buying an additional 23,439 shares in the last quarter. Finally, Bridges Investment Counsel Inc. raised its stake in shares of Gilead Sciences by 58.2% in the first quarter. Bridges Investment Counsel Inc. now owns 18,689 shares of the biopharmaceutical company’s stock worth $1,269,000 after buying an additional 6,875 shares in the last quarter. Hedge funds and other institutional investors own 74.02% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.